Yissum, Ramot, and T3: The Israeli University Technology Transfer Companies Behind Mobileye, Exelon, and Azilect
Israel's universities commercialised academic IP two decades before Bayh-Dole. Yeda 1959, Yissum 1964, Ramot 1973, T3 at the Technion. Mobileye, Exelon, and Azilect all came out of this layer — the one that owns the intellectual property.
Israel Tech Transfer Network · Yissum (Hebrew University, 1964) · Ramot (Tel Aviv University, 1973) · T3 (Technion) · Companion to the Olam profile of Yeda and the Weizmann model.
Israel's research universities were commercialising academic intellectual property two decades before the Bayh-Dole Act made it legal for American universities to do the same. The vehicles they built — Yeda at Weizmann in 1959, Yissum at the Hebrew University in 1964, Ramot at Tel Aviv University in 1973, and T3 at the Technion — are wholly owned commercial subsidiaries that hold their institution's patents outright and license or spin them out. Mobileye came out of Yissum. So did Exelon. Azilect came out of the Technion. This is the layer of the Israeli innovation system that almost never gets named, and it is the one that owns the IP.
Snapshot
| Model | Wholly owned university subsidiary holding title to institutional IP; licenses out and takes equity in spin-outs |
| Yeda | Weizmann Institute, established 1959. The prototype. Longest single-licence revenue tail and the most centralised IP governance of the four |
| Yissum | Hebrew University of Jerusalem, established 1964. Israel's largest TTO by volume: close to 11,500 patents registered, over 1,100 technologies licensed, more than 245 spin-out companies |
| Ramot | Tel Aviv University, established 1973. Owns and commercialises TAU researcher IP. CEO Dr. Ronen Kreizman, appointed 2024 |
| T3 | Technion Technology Transfer, operating under the Technion Research & Development Foundation. Small team — described as roughly eleven people — focused on licensing and company formation |
| Network | Israel Tech Transfer Network (ITTN) — also includes BGN (Ben-Gurion), BIRAD (Bar-Ilan), Carmel-Haifa, Gavish Galilee, Hadasit (Hadassah), Mor Research Applications (Clalit), and Tel Aviv Sourasky |
| Signature assets | Mobileye and BriefCam (Yissum) · Exelon, rivastigmine for Alzheimer's (Yissum) · Azilect, rasagiline for Parkinson's (Technion) · Copaxone (Yeda) |
| Sector aggregate | Historically reported at over NIS 1 billion in annual royalties across Israeli TTOs, roughly 150 technologies licensed and roughly 15 academic-invention companies formed per year |
Aggregate sector figures above derive from published surveys of the Israeli tech-transfer sector and are indicative of scale rather than current-year audited totals. Individual institutional figures are as most recently disclosed by each company.
Why Israel built this first
The Bayh-Dole Act of 1980 is conventionally treated as the origin of modern university technology transfer. Israel's research universities were running the model before it existed. Yeda was established at Weizmann in 1959, Yissum at the Hebrew University in 1964, Ramot at Tel Aviv in 1973 — all predating the American statutory framework, and all built on a structural decision the Americans did not make: the university subsidiary owns the intellectual property outright rather than administering a licensing office on the researcher's behalf.
That ownership structure is the difference. It concentrates negotiating authority, makes equity-for-IP spin-out formation straightforward, and produces long royalty tails that flow back into the institution's research budget rather than to individual faculty. The earliest Israeli transfers were agricultural — research moved to kibbutzim and private farmers, then exported to developing countries — which set the pattern of treating academic output as a commercialisable national asset rather than a publication record.
Yissum — the volume leader
Yissum, founded in 1964 and named for the Hebrew for "application," is Israel's largest technology transfer company by patent count, licence count, and spin-out count: close to 11,500 patents registered, over 1,100 technologies licensed, and more than 245 companies spun out. It has consistently been ranked among the leading academic technology transfer companies worldwide by revenue.
Its portfolio explains why. Exelon — rivastigmine, the Alzheimer's therapy — came out of Hebrew University research and produced sales of $632 million in 2007 alone. The long-shelf-life cherry tomato developed at the university's agricultural faculty has returned on the order of $1 billion to the institution cumulatively, licensed to Hazera and Zeraim Gedera, subsequently acquired by Vilmorin and Syngenta respectively. Mobileye and BriefCam are Yissum spin-outs. Reported Yissum royalty income of roughly $51 million in a single year gives the order of magnitude of the annual flow.
Ramot and T3
Ramot at Tel Aviv University, established 1973, owns the intellectual property created by TAU researchers and runs its commercialisation. Tel Aviv University has ranked among the top hundred universities worldwide for US patents granted, and among the leading non-US institutions in global patent rankings. Dr. Ronen Kreizman was appointed chief executive in 2024.
T3 — Technion Technology Transfer — operates under the Technion Research & Development Foundation with a deliberately small team, described in published accounts as roughly eleven people, positioned as the private sector's route into Technion research. The Technion's most commercially significant single asset is Azilect, the rasagiline compound for Parkinson's disease developed at the institution and commercialised through Teva. The Technion has historically leaned harder toward company formation than pure licensing, which is consistent with its founder-pipeline position across Check Point, Wiz, and Mobileye.
The structural comparison
The four principal vehicles are not interchangeable. Yeda runs the longest single-licence revenue tail and the most centralised IP governance, which is what the Weizmann basic-research model produces — few licences, very large ones, running for decades. Yissum runs the highest volume across the widest sectoral spread, from agricultural genetics to computer vision. Ramot sits closest to a large, broad-based research university with heavy patent throughput. T3 is the most spin-out-weighted and the leanest.
The aggregate matters more than any single vehicle. Published surveys of the sector put Israeli academic technology transfer at over NIS 1 billion in annual royalties, roughly 150 technologies licensed each year, and roughly fifteen new companies founded annually on academic inventions. Against a national research base of seven universities, that is an unusually high conversion rate — and it is the mechanism by which Israeli basic research becomes Israeli corporate equity.
Watch points
- Whether AI-adjacent licensing — computational biology, drug discovery, protein-structure prediction — displaces pharmaceutical royalties as the dominant revenue category across the four vehicles.
- Ramot's direction under Ronen Kreizman, and whether TAU shifts from licensing weight toward spin-out weight.
- Post-October 7 effects on international co-licensing and academic partnership, including boycott exposure at the institutional level.
- Whether any Israeli TTO moves to a fund structure to hold spin-out equity rather than balance-sheet positions.
- Concentration risk: the extent to which each vehicle's royalty income depends on one or two expiring blockbuster licences.
Frequently Asked Questions
What is Yissum?
Yissum is the technology transfer and research development company of the Hebrew University of Jerusalem, founded in 1964. It holds and commercialises the university's intellectual property, with close to 11,500 patents registered, over 1,100 technologies licensed, and more than 245 spin-out companies including Mobileye and BriefCam.
What is Ramot?
Ramot at Tel Aviv University Ltd., established 1973, is Tel Aviv University's technology transfer company. It owns the intellectual property created by university researchers and manages its commercialisation. Dr. Ronen Kreizman was appointed CEO in 2024.
What is T3?
T3 — Technion Technology Transfer — is the Technion's technology transfer unit, operating under the Technion Research & Development Foundation. It licenses Technion intellectual property and forms start-up companies around it.
How is this different from American university technology transfer?
Israel's vehicles predate the 1980 Bayh-Dole Act and are structured as wholly owned subsidiaries that hold title to institutional IP outright, rather than as licensing offices administering researcher-held rights. That concentrates negotiating authority and makes equity-for-IP spin-out formation simpler.
Which Israeli technology transfer company is the largest?
By patents, licences, and spin-outs, Yissum is the largest. By single-licence revenue tail and centralisation of IP governance, Yeda at the Weizmann Institute leads.
Sources
Yissum, Ramot, and T3 corporate disclosures. Israel Tech Transfer Network membership. Published surveys of Israeli academic technology transfer including sector royalty and licensing aggregates. Reporting on Hebrew University technology transfer revenue and the Exelon and tomato-genetics licences. Wikipedia entries on Ramot at Tel Aviv University and T3 Technion Technology Transfer for founding dates and leadership. Olam coverage: Weizmann and the Yeda Model.
